Morgan Stanley Downgrades Halozyme Therapeutics to Equal Weight
Shares of Halozyme Therapeutics (HALO) declined on Wednesday following a rating downgrade by Morgan Stanley. Analyst Sean Laaman lowered the stock's rating from Overweight to Equal Weight, primarily citing valuation concerns in the wake of the company's recent Q3 2026 financial results. Despite the downgrade, the analyst adjusted certain outlook parameters, though the shift reflects a more cautious stance on the current market pricing of Halozyme's Enhanze drug delivery technology. The move comes as investors reassess the growth trajectory and valuation multiples following the latest quarterly update.
